These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32005552)
1. Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas's Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9. Del Giudice F; Catto JWF; Panebianco V Eur Urol; 2020 Apr; 77(4):e94-e95. PubMed ID: 32005552 [No Abstract] [Full Text] [Related]
2. Re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020;77:101-9. Fragkoulis C; Papadopoulos G; Ntoumas K Eur Urol; 2020 Apr; 77(4):e93. PubMed ID: 31980311 [No Abstract] [Full Text] [Related]
3. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Vila-Reyes H; Joel DeCastro G; McKiernan JM Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798 [No Abstract] [Full Text] [Related]
4. Reply to Georgios Papadopoulos, Charalampos Fragkoulis, and Konstantinos Ntoumas' Letter to the Editor re: Bimal Bhindi, Igor Frank, Ross J. Mason, et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017;72:660-4. Bhindi B; Boorjian SA Eur Urol; 2018 Mar; 73(3):e53. PubMed ID: 29246642 [No Abstract] [Full Text] [Related]
5. Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. Panebianco V; Barentsz J; Narumi Y; Catto J; Eur Urol; 2018 Nov; 74(5):e109. PubMed ID: 30029821 [No Abstract] [Full Text] [Related]
6. Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk's Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). Eur Urol 2018;74:294-306. Panebianco V; Barentsz J; Narumi Y; Catto JWF Eur Urol; 2019 Feb; 75(2):e29-e30. PubMed ID: 30471881 [No Abstract] [Full Text] [Related]
7. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO). Necchi A; Messina A; Briganti A Eur Urol; 2018 Nov; 74(5):e107-e108. PubMed ID: 30318068 [No Abstract] [Full Text] [Related]
8. Reply to Georgios Papadopoulos, Georgios Stathouros and Konstantinos Doumas' Letter to the editor Re: Maxine Sun, Marco Bianchi, Jens Hansen, et al. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. Eur Urol 2012;62:696-703. Sun M; Bianchi M; Karakiewicz PI; Trinh QD Eur Urol; 2013 May; 63(5):e65-6. PubMed ID: 23395592 [No Abstract] [Full Text] [Related]
9. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 74, 2018, 294-306. Teoh JYC; Herrmann TRW; Babjuk M Eur Urol; 2019 Feb; 75(2):e27-e28. PubMed ID: 30262343 [No Abstract] [Full Text] [Related]
10. Re: Helena Vila-Reyes, G. Joel DeCastro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36. Panebianco V; Del Giudice F; Narumi Y; Simone G; De Berardinis E; Catto JWF Eur Urol; 2021 Feb; 79(2):e52-e53. PubMed ID: 33261940 [No Abstract] [Full Text] [Related]
11. [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo]. Hechler V; Rink M; Beyersdorff D; Beer M; Beer AJ; Panebianco V; Pecoraro M; Bolenz C; Salomon G Urologe A; 2019 Dec; 58(12):1443-1450. PubMed ID: 31741002 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy and Interobserver Agreement for the Vesical Imaging-Reporting and Data System for Muscle-invasive Bladder Cancer: A Multireader Validation Study. Ueno Y; Takeuchi M; Tamada T; Sofue K; Takahashi S; Kamishima Y; Hinata N; Harada K; Fujisawa M; Murakami T Eur Urol; 2019 Jul; 76(1):54-56. PubMed ID: 30922688 [TBL] [Abstract][Full Text] [Related]
13. Reply to Marco Moschini, Francesco Montorsi, Andrea Salonia, Giorgio Gandaglia and Alberto Briganti's Letter to the Editor Re: Francesco Soria, Matteo Rosazza, Simone Livoti, et al. Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guérin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.10.019. Soria F; Gontero P Eur Urol Focus; 2024 Mar; 10(2):247. PubMed ID: 38278711 [No Abstract] [Full Text] [Related]
14. Reply to Riccardo Lombardo, Sara Riolo, and Cosimo De Nunzio's Letter to the Editor re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6:508-515. D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF; Eur Urol Oncol; 2024 Aug; 7(4):967-968. PubMed ID: 37865570 [No Abstract] [Full Text] [Related]
15. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Vila-Reyes H; DeCastro GJ; McKiernan JM Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975 [No Abstract] [Full Text] [Related]
16. Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Malte W. Vetterlein, Jakob Klemm, Philipp Gild, et al. Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index. Eur Urol 2020;77:55-65: Assessing the Morbidity of Multimodal Approaches in Patients with Muscle-invasive Bladder Cancer. Vetterlein MW; Gild P; Fisch M; Rink M Eur Urol; 2020 Aug; 78(2):e77-e78. PubMed ID: 32376138 [No Abstract] [Full Text] [Related]
17. Reply to Francesco Montorsi and Giorgio Gandaglia's letter to the editor re: Georgios Gakis, Stephen A. Boorjian, Alberto Briganti, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur urol 2014;66:191-9. Gakis G; Stief CG Eur Urol; 2014 Dec; 66(6):e109-10. PubMed ID: 25204223 [No Abstract] [Full Text] [Related]
18. Re: Sungmin Woo, Valeria Panebianco, Yoshifumi Narumi, Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020;3:306-315. Glykas I; Fragkoulis C; Kapogiannis F; Ntoumas K Eur Urol Oncol; 2020 Aug; 3(4):555-556. PubMed ID: 32536572 [No Abstract] [Full Text] [Related]
19. Re: Trey Durdin, Alvin Goh, Eugene Pietzak. Can an Imaging-guided Pathway Replace the Current Paradigm for Muscle-invasive Bladder Cancer? Eur Urol 2021;80:16-7: Transurethral Resection of Bladder Tumor in Diagnosis of Muscle-invasive Bladder Cancer: Old-fashioned Endoscopic Surgery is Here to Stay. Grobet-Jeandin E; Pinar U; Rouprêt M Eur Urol; 2022 Apr; 81(4):e94-e95. PubMed ID: 35031161 [No Abstract] [Full Text] [Related]
20. Reply to Santhanam Sundar's letter to the editor Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-18. Stenzl A; Cowan NC; De Santis M; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA; Lebret T Eur Urol; 2012 Aug; 62(2):e45-6. PubMed ID: 22579356 [No Abstract] [Full Text] [Related] [Next] [New Search]